ES2325996T3 - Uso del factor xiii para estimulacion de la perfusion de tejido isquemico. - Google Patents

Uso del factor xiii para estimulacion de la perfusion de tejido isquemico. Download PDF

Info

Publication number
ES2325996T3
ES2325996T3 ES05715335T ES05715335T ES2325996T3 ES 2325996 T3 ES2325996 T3 ES 2325996T3 ES 05715335 T ES05715335 T ES 05715335T ES 05715335 T ES05715335 T ES 05715335T ES 2325996 T3 ES2325996 T3 ES 2325996T3
Authority
ES
Spain
Prior art keywords
fxiii
fxiiia
perfusion
treated
ischemic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES05715335T
Other languages
English (en)
Spanish (es)
Inventor
Aida Inbal
Rima Dardik
Jonathan Leor
Gerhard Dickneite
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CSL Behring GmbH Deutschland
Original Assignee
CSL Behring GmbH Deutschland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CSL Behring GmbH Deutschland filed Critical CSL Behring GmbH Deutschland
Application granted granted Critical
Publication of ES2325996T3 publication Critical patent/ES2325996T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
ES05715335T 2004-02-20 2005-02-15 Uso del factor xiii para estimulacion de la perfusion de tejido isquemico. Expired - Lifetime ES2325996T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04003950A EP1566183A1 (en) 2004-02-20 2004-02-20 Use of factor XIII for stimulating the perfusion of ischemic tissue
EP04003950 2004-02-20

Publications (1)

Publication Number Publication Date
ES2325996T3 true ES2325996T3 (es) 2009-09-28

Family

ID=34707356

Family Applications (1)

Application Number Title Priority Date Filing Date
ES05715335T Expired - Lifetime ES2325996T3 (es) 2004-02-20 2005-02-15 Uso del factor xiii para estimulacion de la perfusion de tejido isquemico.

Country Status (11)

Country Link
US (1) US20070167361A1 (https=)
EP (2) EP1566183A1 (https=)
JP (1) JP2007523111A (https=)
KR (1) KR20060123567A (https=)
AT (1) ATE429244T1 (https=)
AU (1) AU2005215114B2 (https=)
CA (1) CA2556805C (https=)
DE (1) DE602005014085D1 (https=)
DK (1) DK1718328T3 (https=)
ES (1) ES2325996T3 (https=)
WO (1) WO2005079839A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITTO20130532A1 (it) * 2013-06-27 2014-12-28 Donato Gemmati Nuovo biomarcatore prognostico nell'infarto acuto del miocardio

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU674061B2 (en) * 1993-03-30 1996-12-05 Hoechst Japan Limited Factor XIII for treatment of skin wounds
WO1998051333A1 (en) * 1997-05-14 1998-11-19 Zymogenetics, Inc. Use of factor xiii for the manufacture of a medicament for the treatment of reperfusion injury and mucosal damage
WO2003065997A2 (en) * 2002-02-06 2003-08-14 Vicor Technologies, Inc. Anti-infarction molecules

Also Published As

Publication number Publication date
CA2556805A1 (en) 2005-09-01
DE602005014085D1 (de) 2009-06-04
EP1566183A1 (en) 2005-08-24
JP2007523111A (ja) 2007-08-16
DK1718328T3 (da) 2009-07-27
KR20060123567A (ko) 2006-12-01
AU2005215114A1 (en) 2005-09-01
US20070167361A1 (en) 2007-07-19
EP1718328A1 (en) 2006-11-08
EP1718328B1 (en) 2009-04-22
AU2005215114B2 (en) 2010-05-20
WO2005079839A1 (en) 2005-09-01
CA2556805C (en) 2013-04-02
ATE429244T1 (de) 2009-05-15

Similar Documents

Publication Publication Date Title
Della Rocca et al. An injectable capillary-like microstructured alginate hydrogel improves left ventricular function after myocardial infarction in rats
ES3018357T3 (es) Agente terapéutico para miocardiopatía, el infarto de miocardio previo e insuficiencia cardíaca crónica
RU2647467C2 (ru) Новый способ лечения инфаркта миокарда с применением фрагмента hmgb1
US20070042016A1 (en) Methods and Systems for Treating Injured Cardiac Tissue
ES2556961T3 (es) Células precursoras CD271 derivadas de la médula ósea para reparación cardiaca
US20070093748A1 (en) Methods and systems for treating injured cardiac tissue
WO2006121532A3 (en) Treatment for heart disease
CN102294016B (zh) 治疗血管相关疾病的包含肽的药物组合物
ES2477498T3 (es) Proteína 4 del tipo angiopoyetina (ANGPTL4) para el mantenimiento de la integridad de la barrera celular del endotelio vascular
EA200200850A1 (ru) Фармацевтическая комбинация для лечения повреждения тканей, вызванного недостаточностью артериального кровотока
WO2003053458A1 (es) Uso de una composición farmacéutica que contiene factor de crecimiento epidérmico (egf) para la prevención de la amputación del pie diabético
JP2019141065A (ja) 筋細胞パッチおよびその使用
ES2325996T3 (es) Uso del factor xiii para estimulacion de la perfusion de tejido isquemico.
Jin et al. Extracellular vesicles derived from myocardial infarction plasma inhibit BMSCs apoptosis and enhance cardiac function via AKT signaling pathway
ES2327839T3 (es) Monodosis de fgf-2 eficaz angiogenicamente y metodo de uso.
ES2387682T3 (es) Utilización de un undecapéptido cíclico para la preparación de un medicamento administrable durante situaciones isquémicas miocárdicas
JP2009530411A (ja) 損傷心臓組織治療の方法と方式
KR102890976B1 (ko) 심장줄기세포를 포함하는 허혈성 질환의 예방 또는 치료용 조성물
US20130164847A1 (en) Use of a protein tyrosine kinase inhibitor for inducing the differentiation of mesenchymal stem cells into cardiogenic cells
LeBlanc et al. Targeting the vessel underdogs: therapeutic approaches for microvessel dysfunction in the heart
ES2533475T3 (es) Preparado cardiopléjico
Bello Mechanosensitivity of the failing myocardium: role of mechanical unloading
Lee et al. Clinical application of stem cells for therapeutic angiogenesis in patients with peripheral arterial disease
Ruvinov et al. The Heart—Structure, Cardiovascular Diseases, and Regeneration
DK163175B (da) Synergistisk farmaceutisk kombinationspraeparat af vaevs-plasminogenaktivator, t-pa, og oxypurinol